Slammed 29% Integral Diagnostics Limited (ASX:IDX) Screens Well Here But There Might Be A Catch

Integral Diagnostics Limited (ASX:IDX) shareholders that were waiting for something to happen have been dealt a blow with a 29% share price drop in the last month. The recent drop has obliterated the annual return, with the share price now down 4.9% over that longer period.

Although its price has dipped substantially, there still wouldn't be many who think Integral Diagnostics' price-to-sales (or "P/S") ratio of 1.6x is worth a mention when the median P/S in Australia's Healthcare industry is similar at about 1.7x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.

Check out our latest analysis for Integral Diagnostics

What Does Integral Diagnostics' P/S Mean For Shareholders?

With revenue growth that's inferior to most other companies of late, Integral Diagnostics has been relatively sluggish. Perhaps the market is expecting future revenue performance to lift, which has kept the P/S from declining. If not, then existing shareholders may be a little nervous about the viability of the share price.

If you'd like to see what analysts are forecasting going forward, you should check out our free report on Integral Diagnostics.

Do Revenue Forecasts Match The P/S Ratio?

Integral Diagnostics' P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry.

Taking a look back first, we see that the company managed to grow revenues by a handy 7.7% last year. Pleasingly, revenue has also lifted 36% in aggregate from three years ago, partly thanks to the last 12 months of growth. So we can start by confirming that the company has done a great job of growing revenues over that time.

Turning to the outlook, the next three years should generate growth of 22% each year as estimated by the analysts watching the company. Meanwhile, the rest of the industry is forecast to only expand by 6.7% per year, which is noticeably less attractive.

With this in consideration, we find it intriguing that Integral Diagnostics' P/S is closely matching its industry peers. Apparently some shareholders are skeptical of the forecasts and have been accepting lower selling prices.

The Bottom Line On Integral Diagnostics' P/S

With its share price dropping off a cliff, the P/S for Integral Diagnostics looks to be in line with the rest of the Healthcare industry. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

Despite enticing revenue growth figures that outpace the industry, Integral Diagnostics' P/S isn't quite what we'd expect. There could be some risks that the market is pricing in, which is preventing the P/S ratio from matching the positive outlook. It appears some are indeed anticipating revenue instability, because these conditions should normally provide a boost to the share price.

We don't want to rain on the parade too much, but we did also find 4 warning signs for Integral Diagnostics (2 are potentially serious!) that you need to be mindful of.

If these risks are making you reconsider your opinion on Integral Diagnostics, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.